Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

21 Feb 2017
Change (% chg)

Rs-4.70 (-0.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for REDY.BO


Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)


Beta: 0.16
Market Cap(Mil.): Rs480,222.19
Shares Outstanding(Mil.): 165.67
Dividend: 20.00
Yield (%): 0.69


  REDY.BO Industry Sector
P/E (TTM): -- 28.39 29.32
EPS (TTM): -- -- --
ROI: -- 13.54 13.03
ROE: -- 14.43 14.17

BRIEF-Dr.Reddy's Labs gets form 483 with 3 observations from USFDA for audit of Miryalaguda plant

* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017

21 Feb 2017

BRIEF-Dr.Reddy's Labs says no claims against co for monetary damages

* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"

17 Feb 2017

BUZZ-India's Dr. Reddy's Labs hits over 1-year low; firm's drug infringes U.S. patents

** Shares of Dr Reddy's Laboratories fall as much as 3.9 pct, their lowest since Jan 22, 2016

16 Feb 2017

BRIEF-Dr Reddy's says U.S. court finds co's product infringes some patents

* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement

16 Feb 2017

BRIEF-Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release

* Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories."

27 Jan 2017

MEDIA-South Korean firm sues India's Dr Reddy's in U.S. court - Business Standard

- Note: Reuters has not verified this story and does not vouch for its accuracy

27 Jan 2017

BRIEF-Dr. Reddy's Labs says U.S. FDA re-audit of co's plants part of "usual activity"

* Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants"

12 Jan 2017

BRIEF-Dr.Reddy's Laboratories announces launch of Raloxifene HCI tablets in the U.S.

* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage:

11 Nov 2016

BRIEF-Sucampo Q3 adjusted EPS $0.28

* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance

09 Nov 2016

BUZZ-India's drugmakers decline on worries about possible U.S. probe

** Shares of India's drugmakers fall, sending Nifty Pharma index down as much as 4.5 pct to lowest since June 24

04 Nov 2016

More From Around the Web

Earnings vs. Estimates